文献速递肾移植肾小球疾病

NPHS2基因变异所致激素抵抗型肾病综合征与肾移植后复发无关

Steroid-Resistant Nephrotic Syndrome due to NPHS2 Variants Is Not Associated With Posttransplant Recurrence.
PubMed 文献 · Kidney Int Rep · 2024-01-10

该研究纳入117例携带双等位NPHS2致病变异的肾移植患者,与44例未检出致病变异的激素抵抗型肾病综合征患儿比较。NPHS2组仅1例移植后复发,而无变异组7例(16%)在移植后7天内复发,提示NPHS2相关激素抵抗型肾病综合征移植后复发风险极低。

要点

  • 双等位NPHS2致病变异患者肾移植后肾病综合征复发风险极低。
  • 无致病变异的激素抵抗型肾病综合征患儿移植后复发率较高。
  • 该数据支持对NPHS2相关激素抵抗型肾病综合征患者进行活体肾捐献咨询。

核心结论

  • 携带NPHS2基因致病变异的激素抵抗型肾病综合征患者肾移植后复发风险极低,与裂隙膜内在病变的病理生理一致。

研究设计与样本

  • 研究纳入2010年1月起在Necker-Enfants Malades医院识别的61例及PodoNet注册的56例携带双等位NPHS2变异的肾移植患者,对照为44例无致病变异的激素抵抗型肾病综合征移植患儿。

主要发现

  • 117例NPHS2变异患者中23例为p.Arg138Gln纯合、16例为复合杂合,其余78例为其他变异纯合(n=44)或复合杂合。
  • NPHS2相关激素抵抗型肾病综合征患者中仅1例移植后复发,队列中位随访8.5年(2.5-15)。
  • 无致病变异的44例患者中7例(16%)在移植后最长7天内复发,中位随访8.9年(0.6-13.9)。

临床怎么用

  • 向NPHS2相关激素抵抗型肾病综合征患者咨询时,应告知移植后复发风险极低。
  • 活体肾捐献(无论亲属与否)对NPHS2相关激素抵抗型肾病综合征患者是安全选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Unlike idiopathic nephrotic syndrome (NS), hereditary podocytopathies are not expected to recur after kidney transplantation. However, some reports of posttransplant recurrence of NS in patients carrying variants in the NPHS2 gene have been described, notably with the p.Arg138Gln variant, which is more prevalent in Europe. The objective of this study was to assess the risk of recurrence after kidney transplantation in a large cohort of patients with biallelic NPHS2 pathogenic variants. METHODS: Since January 2010, 61 patients identified at Necker-Enfants Malades Hospital and 56 enrolled in the PodoNet Registry with biallelic variants in the NPHS2 gene were transplanted and were compared with 44 transplanted children with steroid-resistant NS (SRNS) without any identified pathogenic variant. RESULTS: Of the 117 patients, 23 carried the p.Arg138Gln variant in the homozygous state and 16 in the compound heterozygous state. The other 78 patients carried different variants in the homozygous (n = 44) or compound heterozygous state. Only 1 patient with NPHS2-related SRNS experienced posttransplant recurrence (median follow-up of cohort 8.5 years [2.5-15]). Conversely, 7 of 44 patients (16%) without any identified pathogenic variant recurred within a maximum of 7 days after transplantation (median follow-up 8.9 years [0.6-13.9]). CONCLUSION: In this large cohort, the risk of patients with causative variants in the NPHS2 gene to develop NS recurrence after kidney transplantation was extremely low. This is coherent with the pathophysiology of intrinsic slit-diaphragm disease. These data are reassuring and should be considered when counselling patients, making living kidney donation, whether related or not, a safe choice.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kachmar J, Boyer O, Lipska-Ziętkiewicz B, et al. Steroid-Resistant Nephrotic Syndrome due to NPHS2 Variants Is Not Associated With Posttransplant Recurrence. Kidney Int Rep. 2024. PMID: 38765578. doi:10.1016/j.ekir.2024.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。